FDA approve secukinumab for treatment of children and adolescents with moderate to severe plaque psoriasis

Approval for use in patients six years old and over was based on data from two Phase III studies, over 52 and 208 weeks respectively which found that secukinumab improved PASI 75 response by 12 weeks, with a safety profile consistent with previous clinical trials in adults.

Source:

Biospace Inc.